Thomas E. Hutson, DO, Pharm.D., FACP

Grounded in a collaborative and personalized approach, researcher and clinician Dr. Thomas Hutson expands on his best practices for treating certain people living with advanced RCC with a combination therapy.

Researcher and clinician, Dr. Thomas Hutson reflects on the modern patient journey and shares his experience treating people with advanced RCC. Through the years, the advanced RCC treatment landscape has evolved significantly. In this two-part series brought to you by Eisai Inc., hear from oncologist Thomas Hutson, DO as he reflects on best practices for evaluating today’s treatment options.

Dr Thomas Hutson reviews recently published data on patient outcomes and estimated healthcare costs associated with use of third-line cabazitaxel versus a second ARTA in patients with metastatic castration-resistant prostate cancer (CRPC).

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

Thomas Hutson, DO, PharmD, discusses challenges with targeted therapy in non-clear cell renal cell carcinoma.

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

Thomas E. Hutson, DO, PharmD, director of the Genitourinary Oncology Program, Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the efficacy associated with the combination of levantinib (Lenvima) and everolimus (Afinitor) in patients with metastatic renal cell carcinoma (RCC).

Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

Thomas Hutson, DO, PharmD, discusses tivozanib for the treatment of advanced renal cell carcinoma (RCC).